Oupa suggested that “another posible reason for the SP rout perhaps the Virus can impact the P3 trial, patients pulling out because of perceived risks...”
I don’t believe that the SP rout of NEU should be attributed to investor concerns of the impact of COVID-19 on the progress of the trofinetide Phase 3 trial.
If that was the way the general market was thinking, why would Acadia, which is running multiple clinical trials at the moment, have gone up 9.3% overnight?
Over the past week, the NASDQ biotech index (which is full of clinical-trial-running companies) is down 7% and ACAD is off 5.5%.
In comparison, NEU has fallen 33%.
NEU Price at posting:
$1.82 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)